BEACON-AA: Apixaban With or Without Clopidogrel in Stroke Patients With Atrial Fibrillation and Cerebral Atherosclerosis

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 586 participants.

Also called NCT07237308

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 586 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07237308
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07237308. Randomized; single masking; primary purpose prevention. Start 2026-07-14 (actual); primary completion 2029-07-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
BEACON-AA: Apixaban With or Without Clopidogrel in Stroke Patients With Atrial Fibrillation and Cerebral Atherosclerosis
Condition
Stroke
Condition
Ischemic
Condition
Arteriosclerosis
Condition
Intracranial Arteriosclerosis
Intervention (Drug)
Apixaban
Intervention (Drug)
Clopidogrel
Lead sponsor
Yonsei University (class: other)

Record details

Record id
cardio:ct-nct07237308
Content hash
ec17214e9c9eac56f3daf73797146cbc7fbd189fe18bb16c0016e986cf08b4ed